Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary) ; Irinotecan (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results (n=41) assessing toxicity of irinotecan and anlotinib in patients with advanced Ewing sarcoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 21 Feb 2019 Planned number of patients changed from 22 to 47.
- 02 Feb 2018 New trial record